A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
通過10位分析師的專業視角，深入了解拜瑪林製藥
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
過去三個月，有10名分析師提供了拜瑪林製藥（納斯達克：BMRN）的評級，展示了看好和看淡的不同觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級，展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.7, a high estimate of $115.00, and a low estimate of $72.00. A decline of 1.17% from the prior average price target is evident in the current average.
分析師們爲拜瑪林製藥設定了12個月的目標價，揭示了一個平均目標價爲100.7美元，一個高估價爲115美元，一個低估價爲72美元的目標價。相較於前一個平均股價目標，目前的平均目標價下降了1.17%。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：更深入的了解
A comprehensive examination of how financial experts perceive...
最近的分析師行動...
登入免費觀看全文
登入/註冊